An all-oral combination therapy appeared to show promising activity for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with acceptable safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results